RecruitingPhase 1Phase 2NCT06531434

Establishing Best Treatment Strategy for T4 Esophageal Cancer

A Pilot Study to Establish Best Treatment Strategy for T4 Esophageal Cancer

Sponsor

National Cheng-Kung University Hospital

Enrollment

22 participants

Start Date

Aug 1, 2024

Study Type

INTERVENTIONAL

Conditions

Esophageal Cancer TNM Staging Primary Tumor (T) T4

Summary

The goal of this clinical trial is to investigate the safety and efficacy of a new treatment approach for T4-stage esophageal cancer, which involves chemoradiotherapy after induction chemotherapy. The main questions it aims to answer are: * Does the new induction chemotherapy followed by chemoradiation reduce esophageal perforation rate? * Does the new induction chemotherapy followed by chemoradiation increase treatment response rate and patient survival? Researchers will analyze the above data to see if the new treatment approach works to treat T4 esophageal cancer. Participants will: * Receive induction chemotherapy for 4 to 8 cycles, followed by chemoradiation therapy if downstage to T3 * Visit the clinic once every week for checkups and tests * Keep a diary of their symptoms

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at the best treatment strategy for T4 esophageal cancer — a locally advanced type where the tumor has grown into surrounding organs and tissues. It compares different combinations of surgery, chemotherapy, and/or radiation to find the most effective approach. **You may be eligible if...** - You are between 18 and 70 years old - You have confirmed esophageal squamous cell carcinoma (a specific type of esophageal cancer) - Your tumor is T4 stage (has invaded adjacent organs or lymph nodes) - Your general health score is acceptable (ECOG <2) - Your blood counts and organ functions are within required ranges **You may NOT be eligible if...** - You have previously received chemotherapy or radiation for this cancer - Your blood counts or organ functions are outside acceptable limits - Your overall health is too poor - You have another active cancer or serious infection Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

COMBINATION_PRODUCT"Docetaxel", "Cisplatin", "fluorouracil", "Radiation"

Induction chemotherapy with Docetaxel, Cisplatin, and fluorouracil for 4 to 8 cycles, followed by concurrent chemoradiotherapy with Cisplatin and Radiation 30.6-40 Gy.

Locations(1)

National Cheng Kung University Hospital

Tainan, Taiwan, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06531434